Search Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).

Biogen and Sage Therapeutics’ investigational neuroactive steroid did not significantly improve upper limb tremors in patients with essential tremor, the companies announced Wednesday.

Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has signed a Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a leading Saudi company operating in the Middle East and North Africa region.

Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.

Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.

Dementia may be three times more common among people with essential tremor, a movement disorder that causes involuntary shaking, than the general population, according to research released March 6, 2024.

Essential Pharma announces that it has completed the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.

Stimvia, a company specializing in the use of neuromodulation for the treatment of chronic diseases, successfully completed recruitment for a pilot study focused on the treatment of Parkinson’s disease (PD) and essential tremor (ET).

Insightec, a global healthcare company specialising in MR-guided focused ultrasound, announced it has received additional CE mark approval for treatment of essential tremor using its Exablate Neuro platform.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society’s (MDS) International Congress of Parkinson’s Disease and Movement Disorders®, taking place in Copenhagen, Denmark.